Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma

International Journal of Cancer

Volumn 121, Issue 12, 2007, Pages 2668-2673

  Patel, Heena ^a   Polanco Echeverry, Guadalupe ^a   Segditsas, Stefania ^b   Volikos, Emmanouil ^a   McCart, Amy ^a   Lai, Cecilia ^a   Guenther, Thomas ^c   Zaitoun, Abed ^d   Sieber, Oliver ^e   Ilyas, Mohammed ^d   Northover, John ^c   Silver, Andrew ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ST MARK S HOSPITAL   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

AKT; Anal cancer; ASCC; HPV; MDM2; TP53

Indexed keywords

PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53;

ANUS CARCINOMA; ARTICLE; COHORT ANALYSIS; EXON; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; VIRUS INFECTION; WART VIRUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; ALPHAPAPILLOMAVIRUS; AMINO ACID SUBSTITUTION; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; MUTATION; NUCLEAR PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; SEQUENCE DELETION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS;

EID: 36248941256     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23028     Document Type: Article

References (32)

1. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med 2000;342:792-800.
2. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004;101:281-8.
3. Tilston P. Anal human papillomavirus and anal cancer. J Clin Path 1997;50:625-634.
4. Fenger C, Nielsen VT. Precancerous changes in the anal canal epithelium in resection specimens. Acta Pathol Microbiol Immunol Scand [A] 1986;94:63-9.
5. Crook T, Wrede D, Tidy J, Scholefield J, Crawford L, Vousden KH. Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene 1991;6:1251-7.
6. Behrendt GC, Hansmann ML. Carcinomas of the anal canal and anal margin differ in their expression of cadherin, cytokeratins and p53. Virchows Arch 2001;439:782-6.
7. Bonin SR, Pajak TF, Russell AH, Coia LR, Paris KJ, Flam MS, Sauter ER. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer 1999;85:1226-33.
8. Allal AS, Waelchli L, Brundler MA. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res 2003;9:6489-96.
9. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001;20:7874-87.
10. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
11. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40.
12. Yoo J, Park SY, Kang SJ, Shim SI, Kim BK. Altered expression of G1 regulatory proteins in human soft tissue sarcomas. Arch Pathol Lab Med 2002;126:567-73.
13. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002;21:2750-61.
14. Tsuda H, Hashiguchi Y, Nishimura S, Kawamura N, Inoue T, Yamamoto K. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol 2003;91:476-85.
15. Skomedal H, Kristensen GB, Lie AK, Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol 1999;73:223-8.
16. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.
17. Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, McKee PH, Chin L, Bosenberg MW. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006;45:447-54.
18. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
19. Toker A, Yoeli-Lemer M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006;66:3963-6.
20. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82.
21. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
22. Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 2006;118:1877-83.
23. Baay MF, Quint WG, Koudstaal J, Hollema H, Duk JM, Burger MP, Stolz E, Herbrink P. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 1996;34:745-7.
24. Coindre JM, Hostein I, Maire G, Derre J, Guillou L, Leroux A, Ghnassia JP, Collin F, Pedeutour F, Aurias A. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol 2004;203:822-30.
25. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D'Andrea E, Nitti D, Amadori A, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-8.
26. Limesand KH, Schwertfeger KL, Anderson SM. MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells. Mol Cell Biol 2006;26:8840-56.
27. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002;277:21843-50.
28. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y, Ben-Ze'ev A. Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol 2002;64:865-71.
29. Menges CW, Baglia LA, Lapoint R, McCance DJ. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res 2006;66:5555-9.
30. Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ, Richardson CM, Swinson DE, Patel D, Jones JL, O'Byme KJ. Phospho-Akt expression is associated with a favourable outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:2930-6.
31. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson AM, Saad F. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 2006;94:1906-12.
32. Ruiz S, Santos M, Lara MF, Segrelles C, Ballestin C, Paramio JM. Unexpected roles for pRb in mouse skin carcinogenesis. Cancer Res 2005;65:9678-86.